Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 4,113 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Experimental 2 Clear all

Conditions: Covid19, Stage 1 Acute Kidney Injury
Interventions: MIB-626, Placebo, Home Treatment; Drug · Other
Lead sponsor: Metro International Biotech, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gliosarcoma, Newly Diagnosed, Glioblastoma
Interventions: Selinexor, Temozolomide, Generic Radiation therapy (RT), Selective serotonin receptor (5-HT3) antagonists, Olanzapine, Salt tablets, Anti-diarrheal; Drug · Radiation · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pain, Postoperative, Quality of Life
Interventions: Bupivacaine Local Anesthetic; Drug
Lead sponsor: NYU College of Dentistry; Other
Eligibility: 18 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Concussion, Brain, Mild Traumatic Brain Injury
Interventions: EyeBOX Lens (EBLens); Device
Lead sponsor: Oculogica, Inc.; Industry
Eligibility: 17 Years to 35 Years
Enrollment: 1,600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: West Point, New York

Conditions: Visual Acuity
Interventions: etafilcon A Investigational Toric Multifocal Contact Lens; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 7
States / cities: Whittier, California • Orlando, Florida • Kahului, Hawaii + 4 more

Conditions: Hidradenitis Suppurativa
Interventions: Sonelokimab; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 12 Years and older
Enrollment: 835 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 49
States / cities: Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 40 more

Conditions: Schizophrenia
Interventions: Computerized Plasticity-Based Adaptive Cognitive Training, Commercially available computerized training, Optimized social skills training, Unstructured support group sessions; Other
Lead sponsor: Posit Science Corporation; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Obsessive Compulsive Disorder
Interventions: Low Intensity Focused Ultrasound, Sham (No Treatment); Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 22 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Opioid-use Disorder
Interventions: Recovery coach; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Parkinson Disease
Interventions: Osteopathic Manipulative Treatment (OMT), Light Touch; Procedure · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: B-cell Chronic Lymphocytic Leukemia
Interventions: Lenalidomide, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 56
States / cities: Phoenix, Arizona • Fountain Valley, California • San Diego, California + 48 more

Conditions: Metabolic Syndrome
Interventions: Beetroot Juice - Active, beetroot juice - Placebo; Drug
Lead sponsor: Penn State University; Other
Eligibility: 55 Years to 75 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Hernia, Diaphragmatic, Hypertension, Pulmonary, Hypoplasia, Pulmonary
Interventions: sildenafil, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 10 Days to 42 Days
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 3
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois

Conditions: Schizophrenia, Psychotic Disorders
Interventions: Dimethoxybenzylidene anabaseine (DMXB-A), Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Prostate Cancer, HDR
Interventions: High-Dose-Rate Brachytherapy; Procedure
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Cholangiocarcinoma
Interventions: Fimaporfin and Gemcitabine, Gemcitabine/Cisplatin chemotherapy; Drug
Lead sponsor: PCI Biotech AS; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Duarte, California • Atlanta, Georgia • Chicago, Illinois + 3 more

Conditions: Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma, Relapsed/ Refractory T-cell Malignancies
Interventions: Romidepsin, Lenalidomide, CC-486 (5-azacitidine), Dexamethasone, EKG, Bone Marrow Aspiration/Biopsy, MRI, Lumbar Puncture, TTE; Drug · Diagnostic Test · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Anesthesia
Interventions: Negative Connotation Langauge, Positive Connotation Language; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Graves' Disease
Interventions: Experimental: YB-101, Placebo YB-101; Drug
Lead sponsor: Yarrow Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 29
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 26 more

Conditions: Breast Cancer, Breast Tumors, Cancer of Breast
Interventions: Metformin, Atorvastatin, Breast surgery; Drug · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Invasive Aspergillosis, Invasive Pulmonary Aspergillosis
Interventions: Investigational Agent: VL-2397, Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B; Drug
Lead sponsor: Vical; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 11
States / cities: Birmingham, Alabama • La Jolla, California • Sacramento, California + 8 more

Conditions: Spinal Cord Injury, Neuropathic Pain
Interventions: Virtual walking, Wheeling tape; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pleural Mesothelioma, Metastatic Pleural Effusions
Interventions: Adenoviral-mediated Interferon-beta, SCH 721015; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Measles; Mumps; Rubella; Chickenpox, Measles
Interventions: Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, Investigational M(L)M(L)R(L)V(L)NS vaccine, Marketed MMRV_Lot 1 and Lot 2 vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 6 Years
Enrollment: 801 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 35
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • Bellflower, California + 30 more

Search by objective public record fields.

Phase 2a MIB-626 vs. Placebo COVID-19

Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma

Efficacy of Two Local Anesthetics on Quality of Life After Endodontic Treatment

A Highly Portable Device for Assessment of Mild Traumatic Brain Injury in Deployed and Far-Forward Settings

Clinical Evaluation of Multifocal Toric Contact Lenses

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

Creating Live Interactions to Mitigate Barriers

SONATA LIFU for OCD

Initiating Substance Use Disorder Treatment for Hospitalized Opioid Use Disorder Patients.

Effects of Osteopathic Manipulative Treatment (OMT) on Gait Biomechanics in Parkinson's Disease

A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy

Nitrate Supplementation and Cerebrovascular and Cognitive Function in Metabolic Syndrome

Chronic Sildenafil for Severe Diaphragmatic Hernia

Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients

A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence

PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer

Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

Poke and a Placebo

Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease

Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

Virtual Walking for Neuropathic Pain in Spinal Cord Injury

Gene Therapy for Pleural Malignancies

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age